| Autor: |
Tallam, Anil K., Sahithi, Alapati, Nuli, Mohana V. |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Zdroj: |
INTERNATIONAL JOURNAL OF APPLIED PHARMACEUTICAL SCIENCES AND RESEARCH; Vol 8 No 01 (2023): International Journal of Applied Pharmaceutical Sciences and Research; 8-16 |
| ISSN: |
2455-8095 |
| Popis: |
Recent breakthroughs in peptide exploration have led to revolutionary medicinal discoveries for a number ofdifferent infectious illnesses. An immediate need exists for the development of viable treatment alternativesin light of the continuing danger of the COVID-19 pandemic. Peptide inhibitors have notable potential for themanagement of developing viral infections since they are safe, effective, and selective. Antiviral peptides maybe rationally engineered and optimally formulated using information about the 3D structures of viral proteinsand the cells they target. The resultant peptides may have broad antiviral action or be extremely selective forcertain targets and targeted viral infections. In this article, we discuss the research done so far on severe acuterespiratory syndrome coronavirus 2 (SARS-CoV-2) peptide medicines. Thus far, attempts to repurpose peptidemedicines with antiviral and antibacterial properties have failed. Targeting the link between the SARS-CoV-2spike protein and the ACE-2 (Angiotensin-Converting Enzyme-2) that initiates cellular infection and viralreplication has yielded the most promising discoveries, albeit by no means the only ones. While there exists noapproved therapy for SARS-CoV-2, the experience gained in developing peptide drugs for this virus suggeststhat this approach may now be preferable to the use of smaller molecules. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
